HSV-2 is a lifelong infection that causes recurrent genital ulcers and on rare occasions, disseminated and visceral disease, including hepatitis and pneumonitis. Host immune responses are critical determinants in the clearance of herpetic lesions. 1 The corollary of this is that immunocompromised hosts, who lack such a response, may develop either high frequency of viral shedding or persistent, poorly healing genital lesions.
The nucleoside analogue aciclovir (ACV) is the antiviral drug of choice for the treatment and prophylaxis of HSV. In the setting of allogeneic HSCT it is often used to reduce symptomatic reactivation of both HSV and VZV, 2 --4 and symptomatic HSV infection is reduced from about 70% to 5 --20%. 5 However, ACV resistance due to mutations in viral DNA polymerase or more commonly thymidine kinase may develop. 6 In immunocompromised patients, the prevalence of HSV infections with ACV resistance ranges from 3.5 to 25%, with the very highest rates reported in recipients of a HSCT. 7 In ACV-resistant HSV, antiviral agents, such as Foscarnet (phosphono-formic acid (PFA)) and Cidofovir (CDV), are available but their use is limited by toxicity and drug resistance. There is a clear need for new antiviral agents.
The antimalarial artesunate has recently been shown to be effective against some human herpesvirues through unclear mechanisms which appear to be active against host rather than viral targets. 8 However, there is little data on the activity of artesunate against HSV-2 from in vitro studies, and there are no previous reports detailing outcomes following use of artesunate to treat HSV-2 in the clinic. Here we describe, to our knowledge, the first clinical use of artesunate for the treatment of a multidrugresistant HSV-2 infection in an immunocompromised patient.
An 18-year-old female received a T-cell-depleted HSCT for treatment of resistant nodular sclerosing Hodgkin Lymphoma. Her donor was an unrelated male matched at 10/10 HLA loci. Both donor and recipient were seronegative for CMV. She engrafted on day þ11 after stem cell infusion. Throughout this period, she remained on prophylactic immunosuppression with CYA and received our standard prophylaxis with ACV (200 mg p.o. thrice daily). By day þ 15 she had developed superficial ulceration of the perineum and left labia. PCR testing of swabs revealed HSV-2 infection. The prophylactic ACV was changed to valACV 1 g p.o. twice daily. Despite this treatment her lesions progressed and she was converted to i.v. PFA on day þ 45. HSV-2 DNA was also detected by PCR in the serum.
At this time she developed Grade II cutaneous GvHD, which responded to a short course of oral prednisolone. As impaired renal function dictated a reduction in cyclosporine dose, mycophenolate mofetil was introduced as a further immunosuppressant to control GvHD and cover steroid withdrawal. By day þ58 PFA was discontinued because of a rising creatinine but by this point the lesions had almost resolved and PCR of venous blood was negative for HSV-2. She was converted back to prophylactic ACV. Herpetic lesions returned within days and a repeat swab was still positive for HSV-2. She was commenced on topical PFA thrice daily with some improvement. However, within 2 weeks of discontinuing topical PFA she developed multiple punched-out ulcers in the perianal region. At this time HSV-2 from the patient was cultured, titrated and assessed for drug susceptibility by plaque reduction assay and found to be resistant to ACV, penciclovir and PFA but sensitive to CDV (Virus Reference Department, Health Protection Agency, Colindale, London, UK). By 4.5 months aftert transplant, despite reintroduction of topical PFA, the lesions had continued to extend throughout the perineum and sacral area. She commenced weekly i.v. CDV (5 mg/kg) with marked improvement initially. However, by the seventh dose of CDV the lesions had returned bilaterally, with perianal and perivulvar involvement. Topical CDV (1%) was added to weekly i.v. CDV, but 4 weeks later there was clearly a decreasing clinical response. Drug susceptibility testing of a concurrent clinical isolate revealed that the virus remained resistant to ACV, penciclovir and PFA but sensitive to CDV despite increasing clinical resistance.
In view of a case report suggesting activity in multidrugresistant CMV 9 and in vitro data supporting activity against HSVs, 8 oral artesunate 100 mg once daily was commenced. CDV had been discontinued 7 days earlier due to clinical progression and lack of venous access. Within 4 days of starting artesunate the lesions were less painful. She was reviewed 2 weeks after completing 30 days of artesunate. The lesions had completely resolved. Furthermore, PCR from a perineal swab was negative for HSV-2 for the first time since the lesions had appeared 49 months previously. Approximately 1 month later (day þ 332) there was a return of perineal pain and numerous small herpetic ulcers, confirmed virologically. Once again, oral artesunate 100 mg once daily was commenced and resulted in rapid resolution of the lesions and a further swab was then negative for HSV-2. A third reactivation of HSV-2 also responded rapidly to artesunate. There were no problems with drug toxicity, in keeping with previous reports on the treatment of malaria. 10 The complete treatment history along with details of immune suppression and lymphocyte count is detailed in Figure 1 . It is noteworthy that around the time of first artesunate treatment and resolution of the HSV-2, there was both a reduction in immunosuppression and a gradual rise in lymphocyte count. With such confounding factors there is difficulty in ascribing causality of lesion resolution to artesunate therapy during the first-treatment episode, though the speed of resolution and temporal relationship to starting artesunate were highly suggestive. However, the two subsequent episodes of symptomatic ulceration, confirmed to relate to HSV-2, and successful resolution following re-institution of artesunate occurred in the absence of changes in immunosuppression or significant changes in lymphocyte count, providing strong inferential support to the argument that artesunate had a significant role in the control of HSV-2 infection during all three episodes without loss of efficacy. We believe that artesunate deserves further evaluation in the management of these challenging patients.
